FRENCH RUMORS ON GLAXO'S SUMATRIPTAN
Since the International Headache Conference took place in France last month, rumors have been circulating that the French government wants to renegotiate the agreement regarding the marketing of Glaxo's antimigraine agent Imigran (sumatriptan), which is still to be launched in Fance.
A Glaxo spokesperson told the Marketletter that as far as the company is concerned nothing has changed regarding the situation in France, and it has not been approached by the French government concerning sumatriptan.
A deal was worked out with the former socialist government and a price was agreed but the product is still not available on the French market. In 1992, former president of Glaxo France Edwin Nathan departed the company for reasons that were understood to be linked to Glaxo France's stance over French drug pricing.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze